Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction

Cardiac Intensive Care

Volumn , Issue , 2010, Pages 110-144

  Gogo, Prospero B ^a   Dauerman, Harold L ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053650280     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3773-6.10012-6     Document Type: Chapter

References (321)

1. Herrick J.B. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912, 59:2015-2020.
2. Roberts W.C. Coronary arteries in fatal acute myocardial infarction. Circulation 1972, 45:215-230.
3. Chazov E.L., Matteeva L.S., Mazaev A.V., et al. Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh 1976, 48:8-19.
4. Rentrop P., Blanke H., Karsch K.R., et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase in combination with transluminal recanalization. Clin Cardiol 1979, 2:354-363.
5. Sobel B.E., Braunwald E. The management of acute myocardial infarction. Heart Disease 1983, 1301-1333. Saunders, Philadelphia. 2nd ed. E. Braunwald (Ed.).
6. Maroko P.R., Kjekshus J.K., Sobel B.E., et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971, 43:67-82.
7. WHO-MONICA Project Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates and care fatality rates in 38 populations from 21 countries in four continents. Circulation 1994, 90:583-612.
8. A randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986, 2:57-66. ISIS-1 Collaborative Group.
9. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo-controlled international trial. Eur Heart J 1985, 6:199-226. MIAMI Trial Research Group.
10. Anderson M.P., Bechsgaard P., Frederiksen J., et al. Effects of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: preliminary results. Lancet 1979, 2:865-872.
11. Hjalmarson Å., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981, 2:823-827.
12. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984, 310:9-15. International Collaborative Study Group.
13. Peter T., Norris R., Clark E., et al. Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation 1978, 57:1091-1095.
14. Roberts R., Croft C., Gold H.K. MILIS Study Group: Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. N Engl J Med 1984, 311:218-225.
15. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005, 366:1607-1621.
16. Yusuf S., Collins R., MacMahon S., et al. Effect of IV nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1988, 1:1088-1092.
17. Dauerman H.L., Lessard D., Yarzebski J., et al. Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction. Am J Cardiol 2000, 86:730-735.
18. Furman M.I., Dauerman H.L., Goldberg R.J., et al. Twenty-two year (1975-1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001, 37:1571-1580.
19. Blumgart H.L., Gilligan R., Schlesinger M.J. Experimental studies on the effect of temporary occlusion of coronary arteries, II: the production of myocardial infarction. Am Heart J 1941, 22:374-389.
20. Sobel B.E., Breshnahan G.F., Shell W.E., Yoder R.D. Estimation of infarct size in man and its relation to prognosis. Circulation 1972, 46:640-648.
21. Geltman E.M., Ehsani A.A., Campbell M.K., et al. The influence of location and the extent of myocardial infarction on long term ventricular dysrhythmia and mortality. Circulation 1979, 60:805-814.
22. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994, 90:2126-2146.
23. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2 parts). N Engl J Med 1992, 326:242-250. 310-318.
24. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res 1966, 6:1-7.
25. Roberts W.C., Buja L.M. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction. Am J Med 1972, 52:425-443.
26. DeWood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of acute myocardial infarction. N Engl J Med 1980, 303:897-902.
27. Mizuno K., Satomura K., Miyamato A., et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992, 326:287-291.
28. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980, 43:77-89.
29. Neuhaus K-L., Rainer V.E., Ulrich T., et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992, 19:885-891.
30. GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:1615-1622.
31. Weaver D.W., Cerqueira M., Hallstrom A., et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The MITI trial. JAMA 1993, 270:1211-1216.
32. Fuster V., Badimon L., Cohen M., et al. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988, 77:1213-1220.
33. Stein B., Fuster V., Halperin J.L., Chesebro J.H. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989, 80:1501-1513.
34. Sherry S., Fletcher A., Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol Rev 1959, 39:343-382.
35. Nossel H.L., Ti M., Kaplan K.L. The generation of fibrinopeptide A in clinical blood samples. J Clin Invest 1976, 58:1136-1141.
36. Nossel H.L., Wasser J., Kaplan K.L. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. J Clin Invest 1979, 64:1371-1378.
37. 1 + 2 fragment and thrombin-antithrombin complex. Blood 1982, 59:1086-1097.
38. Brower M., Harpel P. Alpha-1 antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin complexes. Blood 1983, 61:842-849.
39. Pizzo S.V., Taylor L.M., Schwartz M.L., et al. Subunit structure of fragment D from fibrinogen and cross-linked fibrin. J Biol Chem 1973, 248:4584-4590.
40. Francis C.W., Marder V.J., Martin S.E. Plasmic degradation of cross-linked fibrin, I: structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood 1980, 66:456-464.
41. Collen D., Linjen H.R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991, 78:3114-3124.
42. Eisenberg P.R., Sherman L., Rich M., et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986, 7:1255-1262.
43. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1989, 86:7585-7589.
44. Lee C.D., Mann K.G. The activation of human coagulation factor V by plasmin. Blood 1989, 73:185-190.
45. Eisenberg P.R., Miletick J.E., Sobel B.E., Jaffe A.S. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue plasminogen activator (t-PA). Thromb Res 1988, 50:707-717.
46. Schneider D.J., Sobel B.E. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 2007, 116:305-315.
47. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med 1990, 322:33-42.
48. Sobel B.E., Nachowiak D.A., Fry E.T.A., et al. Paradoxical attenuation of fibrinolysis attributable to "plasminogen steal" and its implications for coronary thrombolysis. Coron Artery Dis 1990, 1:111-119.
49. Reddy K.N.N. Mechanism of activation of human plasminogen by streptokinase. Fibrinolysis 1980, 71-94. CRC Press, Boca Raton, FL. D.L. Kline, K.N.N. Reddy (Eds.).
50. Collen D., Verstraete M. Thrombolytic agents. Coronary Thrombolysis in Perspective 1993, 11-33. Marcel Dekker, New York. B.E. Sobel, D. Collen (Eds.).
51. Summaria L., Wohl R.C., Boreisha I.G., Robbins K.C. A virgin enzyme derived from human plasminogen: specific cleavage of the arginyl-560-valyl peptide bond in the disopropoxyphosphinyl virgin enzyme by plasminogen activators. Biochemistry 1982, 21:2056-2059.
52. Markus G., DePasquale J.L., Wissler F.C. Quantitative determination of the binding of the ε-aminocaproic acid to native plasminogen. J Biol Chem 1978, 253:727-732.
53. Cowley M.J., Hastillo A., Vertrovee G.W., et al. Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency. Circulation 1983, 67:1031-1038.
54. Verstraete M., Vermylen J., Amery A., Vermylen C. Thrombolytic therapy with streptokinase using a standard dosage scheme. BMJ 1966, 5485:454-456.
55. Fears R., Hearn J., Standring R., et al. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J 1992, 124:305.
56. Fears R., Ferres H., Glasgow E., et al. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992, 68:167-170.
57. Jalihal S., Morris G.K. Antistreptokinase titres after intravenous streptokinase. Lancet 1990, 335:184-185.
58. Goa K.L., Henwood J.M., Stoltz J.F., et al. Intravenous streptokinase: a reappraisal of its therapeutic use in acute myocardial infarction. Drugs 1990, 39:693-719.
59. Lew A.S., Laramee P., Cercek B., et al. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation 1985, 72:1321-1326.
60. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988, 2:349-360. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
61. Schroder R., Biamino G., Leitner E-R.V., et al. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 1983, 67:536-548.
62. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico (GISSI) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986, 1:397-402.
63. Smith R.A.G., Dupe R.J., Enligh P.D., Green J. Fibrinolysis with acyl enzymes: a new approach to thrombolytic therapy. Nature 1981, 290:505-508.
64. Collen D., Verstraete M. Pharmacology of thrombolytic drugs. Hurst's the Heart 1994, 1327. McGraw-Hill, New York. 8th ed. R.C. Schant, R.W. Alexander (Eds.).
65. White W.F., Barlow G.H., Mozen M.M. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966, 5:2160-2169.
66. Mathey D.G., Schofer J., Sheehan F.H., et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985, 55:878-882.
67. Collen D., Rijken D.C., Van Damme J., Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemost 1982, 48:294.
68. van de Werf F., Ludbrook P.A., Bergmann S.R., et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984, 310:609-613.
69. Pennica D., Holmes W.E., Kohr W.J., et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983, 301:214.
70. Collen D., Topol E.J., Tiefenbrunn A.J., et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984, 70:1012-1017.
71. Eisenberg P.R., Sherman L.A., Tiefenbrunn A.J., et al. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemost 1987, 57:35-40.
72. Chmielewska J., Ranby M., Winman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983, 31:427.
73. Verheijen J.H., Chang G.T.G., Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984, 51:392.
74. Kruithof E.K.O., Tran-Thang C., Ransigm A., Bachman F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984, 64:907-913.
75. Lucore C.L., Sobel B.E. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988, 77:660-669.
76. Topol E.J., Ciuffo A.A., Pearson T.A., et al. Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion. J Am Coll Cardiol 1985, 5:85-91.
77. Topol E.J., Bell W.R., Weisfeldt M.L. Coronary thrombolysis with recombinant tissue plasminogen activator: a hematologic and pharmacologic study. Ann Intern Med 1985, 103:837-843.
78. Higgins D.L., Vehar G.A. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin degraded fibrin. Biochemistry 1987, 26:7786-7791.
79. Rijken D.C., Hoylaerts M., Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982, 257:2920-2925.
80. Tate K.M., Higgins D.L., Holmes W.E., et al. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987, 26:338-343.
81. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989, 320:618-627. TIMI Study Group.
82. Neuhaus K-L., Feuerer W., Jeep-Tebbes S., et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989, 14:1566-1569.
83. Lack C.H. Staphylokinase: an activator of plasma protease. Nature 1948, 161:559-560.
84. Lewis J.H., Kerber C.W., Wilson J.H. Effects of fibrinolytic agents and heparin on intravascular clot lysis. Am J Physiol 1964, 207:1044-1048.
85. Kanai K. Fibrinolysis by staphylokinase in vivo [Abstract 65436]. Biol Abstr 1986, 81:748.
86. Matsuo O., Okada K., Fukao H., et al. Thrombolytic properties of staphylokinase. Blood 1990, 76:925-929.
87. Lijnen H.R., Van Hoef B., De Cock F., et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991, 266:11826-11836.
88. Collen D., De Cock F., Stassen J.M. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993, 87:996-1006.
89. Collen D., Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993, 87:1850-1853.
90. Martin U., Kohler J., Sponer G., Strein K. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs and non-human primates. Fibrinolysis 1992, 6:17-25.
91. Martin U., Sponer G., Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase, and urokinase in a canine model of coronary thrombosis. J Am Coll Cardiol 1992, 19:433-440.
92. Neuhaus K-L., von Essen R., Vogt A., et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol 1994, 24:55-60.
93. Tebbe U., von Essen R., Smolarz A., et al. Open, non-controlled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993, 72:518-524.
94. Lijnen H.R., Collen D. Tissue-type plasminogen activator: mutants, variants and adjunctive treatment. Biotechnol Ther 1990, 1:273-304.
95. Collen D. Towards improved thrombolytic therapy. Lancet 1993, 342:34-36.
96. Binbrek A.S., Rao N.S., Neimane D., et al. Comparison of rapidity of coronary recanalization in men with tenecteplase-vs-alteplase in acute myocardial infarction. Am J Cardiol 2004, 93:1465-1468.
97. Rentrop P., Blanke H., Karsch K.R., et al. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981, 63:307-317.
98. Rentrop P., Feit F., Blanke H. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med 1984, 311:1458-1463.
99. Kennedy J.W., Ritchie J.L., Davis K.B., Fritz J.K. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983, 309:1477-1482.
100. Collen D., Topol E.J., Tiefenbrunn A.J., et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984, 70:1012-1017.
101. Williams D.O., Borer J., Braunwald E., et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986, 73:338-346.
102. Rogers W.J., Mantle J.A., Hood W.P., et al. Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction. Circulation 1983, 68:1051-1061.
103. Sezer M., Oflaz H., Goren T., et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007, 356:1823-1834.
104. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in acute myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987, 76:142-154.
105. Califf R.M., O'Neil W., Stack R.S. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988, 108:658-662.
106. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985, 312:932-936. TIMI Study Group.
107. Ito H., Tomooka T., Sakai N., et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992, 85:1699-1705.
108. Timmis A.D., Griffin B., Crick J.C., Sowton E. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol 1987, 10:205-210.
109. Anderson J.L., Marshall H.W., Askins J.C., et al. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction. Circulation 1984, 70:606-618.
110. Topol E.J., Morris D.C., Smalling R.W., et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol 1987, 9:1205-1213.
111. Verstraete M., Brower R.W., Collen D., et al. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction (ECSG-2). Lancet 1985, 2:965-969.
112. Cribier A., Berland J., Saoudi N., et al. Intracoronary streptokinase, agreed: .. intravenous streptokinase, first? Heparin or intravenous streptokinase in acute infarct: preliminary results of a prospective randomized trial with angiographic evaluation in 44 patients. Haemostasis 1986, 16:122-129.
113. Bassand J.P., Machecourt J., Pruvost P., et al. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. J Am Coll Cardiol 1989, 13:988-997.
114. Van de Werf F., Arnold A.E. European Cooperative Study Group: Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction (ECSG-5). BMJ 1988, 297:1374-1379.
115. Granger C.B., Califf R.M., Topol E.J. Thrombolyic therapy for acute myocardial infarction: a review. Drugs 1992, 44:293-325.
116. Topol E.J. Thrombolytic intervention. Textbook of Interventional Cardiology 1994, vol I:68-111. Saunders, Philadelphia. 2nd ed. E.J. Topol (Ed.).
117. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded?. Circulation 1989, 79:441-444.
118. Fortin D.F., Califf R.M. Long-term survival from acute myocardial infarction: salutary effect of an open coronary vessel. Am J Med 1990, 88:9-15.
119. Karagounis L., Sorensen S.G., Menlove R.L., et al. TEAM-2 Investigators: Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992, 19:1-10.
120. Vogt A., von Essen R., Tebbe U., et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993, 21:1391-1395.
121. GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615-1622.
122. Carney R.J., Murphy G.A., Brandt T.R. RAAMI Investigators: Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. J Am Coll Cardiol 1992, 20:17-23.
123. Fox K.A.A., Robinson A.K., Knabb R.M., et al. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1985, 72:1346-1354.
124. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986, 314:1465-1471. ISAM Study Group.
125. Bassand J-P., Faivre R., Becque O., et al. Effects of early high dose streptokinase intravenously in acute myocardial infarction. Am J Cardiol 1987, 60:435-439.
126. Kennedy J.W., Martin G.V., Davis K.B., et al. The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 1988, 77:345-352.
127. White H.D., Norris R.M., Brown M.A., et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987, 317:850-855.
128. O'Rourke M., Baron D., Kelly K.R., et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988, 77:1311-1315.
129. Armstrong P.W., Baigrie R.S., Daly P.A., et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989, 13:1469-1476.
130. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1988, 1:203-208. National Heart Foundation of Australia Coronary Thrombolysis Group.
131. Bates E.R., Topol E.J., Kline E.M., et al. Early reperfusion therapy improves left ventricular function after acute inferior myocardial infarction associated with right coronary disease. Am Heart J 1987, 114:261-267.
132. Schroder R., Neuhaus K-L., Linderer T., et al. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study). Am J Cardiol 1989, 64:878-884.
133. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1989, 1:1367-1368.
134. Norris R.M., White H.D. Therapeutic trials in coronary thrombosis should measure left ventricular function as a primary end-point of treatment. Lancet 1988, 1:104-106.
135. Lincoff A.M., Topol E.J. Trickle down thrombolysis. J Am Coll Cardiol 1993, 21:1396-1398.
136. Topol E.J., Califf R.M., Vandormael M., et al. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group: A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992, 85:2090-2099.
137. Wilcox R.G., Olsson C.G., Skene A.M., et al. ASSET Study Group: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988, 2:525-530.
138. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988, 1:545-549. AIMS Trials Study Group.
139. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after the onset of acute myocardial infarction. Lancet 1993, 342:759-766. LATE Study Group.
140. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993, 342:767-772. EMERAS Collaborative Group.
141. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from randomized trials of more than 1000 patients. Lancet 1994, 343:311-322. Fibrinolytic Therapy Trialists Collaborative Group.
142. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardico GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990, 336:65-71.
143. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992, 339:753-770. Third International Study of Infarct Survival Collaborative Group.
144. Kroon C., ten Hove W.R., de Boer A., et al. Highly variable anticoagulant response after subcutaneous administration of high dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 1992, 86:1370-1375.
145. Hsia J., Hamilton W.P., Kleiman N., et al. HART Investigators: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990, 323:1433-1437.
146. Topol E.J., George B.S., Kereiakes D.J., et al. TAMI Study Group: A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989, 79:281-286.
147. Hsia J., Kleiman N., Aguirre F., et al. HART Investigators: Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 1992, 20:31-35.
148. Arnout J., Simoons M., De Bono D., et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase. J Am Coll Cardiol 1992, 20:513-519.
149. Bleich S.D., Nichols T.C., Schumacher R.R., et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990, 66:1412-1417.
150. de Bono D.P., Simoons M.L., Tijssen J., et al. European Cooperative Study Group: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial (ECSG-6). Br Heart J 1992, 67:122-128.
151. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990, 336:71-75. International Study Group.
152. Califf R.M., Topol E.J., Stack R.S., et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) phase 5 randomized trial. Circulation 1991, 83:1543-1556.
153. Grines C.L., Nissen S.E., Booth D.C., et al. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full dose tissue-type plasminogen activator. Circulation 1991, 84:540-549.
154. Topol E.J., Califf R.M., George B.S., et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 1988, 77:1100-1107.
155. Tiefenbrunn A.J., Sobci B.E. Timing of coronary recanalization: paradigms, paradoxes, and pertinence. Circulation 1992, 85:2311-2315.
156. Sobel B.E., Shell W.E. Jeopardized, blighted and necrotic myocardium. Circulation 1973, 47:215-216.
157. Weaver W.D., Eisenberg M.S., Martin J.S., et al. Myocardial infarction triage and intervention project-phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990, 15:925-931.
158. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993, 329:383-389. European Myocardial Infarction Project (EMIP) Group.
159. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ 1992, 305:548-553. GREAT Group.
160. Thiele H., Scholz M., Engelmann L., et al. ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention. Am J Cardiol 2006, 98:1132-1139.
161. Svensson L., Aasa M., Dellborg M., et al. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. Am Heart J 2006, 151:798.e1-798.e7.
162. Stenestrand U., Lindback J., Wallenstein L. RIKS-HIA Registry: Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006, 296:1749-1756.
163. Bonnefoy E., Lapostolle F., Leizorovicz A., et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002, 360:825-829.
164. Sinnaeve P.R., Huang Y., Bogaerts K., et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-2 PLUS. Am Heart J 2006, 152:684.e1-684.e9.
165. Sobel B.E., Hirsch J. Principles and practice of coronary thrombolysis and conjunctive treatment. Am J Cardiol 1991, 68:382-388.
166. Haskel E.J., Adams S.P., Feigen L.P., et al. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation 1989, 80:1775-1782.
167. Jang I-K., Gold H.K., Ziskind A.A., et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989, 79:920-928.
168. Gold H.K., Coller B.S., Yasuda T., et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988, 77:670-677.
169. Coller B.S., Folts J.D., Smith S.R., et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GP IIb/IIIa receptors. Circulation 1989, 80:1766-1774.
170. Yasuda T., Gold H.K., Leinbach R., et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP IIb/IIIa antibody. J Am Coll Cardiol 1990, 16:1728-1735.
171. Yasuda T., Gold H.K., Fallon J.T., et al. Monoclonal antibody against
172. Kleiman N.S., Ohman E.M., Califf R.M., et al. Profound aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993, 22:381-389.
173. Topol E.J., Califf R.M., Weisman H.F., et al. EPIC investigators: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinic restenosis: results at six months. Lancet 1994, 343:881-886.
174. Faulds D., Sorkin E.M. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 1994, 48:583-598.
175. McLean D.S., Sabatine M.S., Guo W., et al. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis 2007, 24:85-91.
176. Eisenberg P.R., Sherman L., Rich M., et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986, 7:1255-1262.
177. Hirsch J. Heparin. N Engl J Med 1991, 324:1565-1574.
178. Weitz J.I., Hudoba M., Massel D., et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
179. Maraganore J.M., Bourdon P., Jablonski J., et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29:7095-7101.
180. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605-613.
181. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007, 49:2238-2246.
182. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295:1519-1530.
183. Yusuf S., Mehta S.R., Chrolavicius S., et al. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476.
184. Maraganore J.M., Chao B., Joseph M.L., et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989, 264:8692-8698.
185. Heras M., Chesebro J.H., Webster M.W.I., et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990, 82:1476-1484.
186. Agnelli G., Pascucci C., Cosmi B., Nenci G.G. The comparative effects of recombinant hirudin (GP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990, 63:204-207.
187. Badimon L., Badimon J., Lassila R., et al. Thrombin inhibition by hirudin decreases platelet thrombus growth on areas of severe vessel wall injury [Abstract]. J Am Coll Cardiol 1989, 13:145A.
188. Haskel E.J., Prager N.A., Sobel B.E., Abendschein D.R. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991, 83:1048-1056.
189. Global Use of Strategies to Open Occluded Arteries (GUSTO) IIa Investigators Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637.
190. Antman E.M. TIMI.9A Investigators: Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in acute myocardial infarction (TIMI) 9A trial. Circulation 1994, 90:1624-1630.
191. Neuhaus K-L., Essen R.V., Tebbe U., et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994, 90:1638-1642.
192. Sobel B.E. Intracranial bleeding, fibrinolysis, and anticoagulation: causal connections and clinical implications. Circulation 1994, 90:2147-2152.
193. Stella J.F., Stella R.E., Iaffaldano R.A., et al. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol 2004, 16:451-454.
194. Saw J., Lincoff A.M., Desmet W., et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol 2004, 44:1194-1199.
195. Chew D.P., Lincoff A.M., Gurm H., et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005, 95:581-585.
196. Stone G.W., Bertrand M., Colombo A., et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: study design and rationale. Am Heart J 2004, 148:764-775.
197. Edmond J.J., French J.K., Aylward P.E., et al. Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. Eur Heart J 2007, 28:1418-1424.
198. Popma J.J., Topol E.J. Adjuncts to thrombolysis for acute myocardial infarction. Ann Intern Med 1991, 115:34-44.
199. Popma J.J., Topol E.J. Adjuncts to thrombolysis: current opinions and future directions. Prim Cardiol 1991, 17:65-68.
200. Eisenberg P.R. Development of novel anticoagulants for use as conjunctive therapy for thrombolysis. Coron Artery Dis 1992, 3:1010-1015.
201. Zoldhelyi P., Fuster V., Chesebro J.H. Antithrombins as conjunctive therapy in arterial thrombolysis. Coron Artery Dis 1992, 3:1003-1009.
202. Sobel B.E., Collen D. Strokes, statistics, sophistry in trials of thrombolysis for acute myocardial infarction. Am J Cardiol 1993, 71:424-427.
203. Thompson P.L., Robinson J.S. Stroke after acute myocardial infarction: relation to infarct size. BMJ 1978, 2:457-459.
204. Komrad M.S., Coffey C.E., Coffey K.S., et al. Myocardial infarction and stroke. Neurology 1984, 34:1403-1409.
205. Veterans Administration Cooperative Study Anticoagulants in acute myocardial infarction: results of a cooperative trial. JAMA 1973, 225:724-729.
206. Tiefenbrunn A.J., Ludbrook P.A. Coronary thrombolysis-it's worth the risk. JAMA 1989, 261:2107-2108.
207. Sloan M.A., Gore J.M. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1992, 69:21A-38A.
208. Sobel B.E., Collen D. Questions unresolved by the Third International Study of Infarct Survival. Am J Cardiol 1992, 70:385-389.
209. Operations Committee TIMI, Braunwald E., Knatterud G.L., et al. Update from the Thrombolysis in Myocardial Infarction trial. J Am Coll Cardiol 1987, 10:970.
210. Collins R., Peto R., Parish S., Sleight P. After ISIS-3: reply. Lancet 1992, 339:1226-1227.
211. Sobel B.E. Clarifying the conundrum of conjunctive anticoagulation and coronary thrombolysis. Coron Artery Dis 1995, 6:83-86.
212. Thompson P.L., Aylward P.E., Federman J., et al. National Heart Foundation of Australia Coronary Thrombolysis Group: A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991, 83:1534-1542.
213. DeJaegere P.P., Arnold A.A., Bulk A.H., Simoons M.L. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992, 19:289-294.
214. Maggioni A.P., Franzosi M.G., Santro E., et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992, 327:1-6. GISSI-2 Study Group.
215. Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 1990, 82:1510-1513.
216. Fennerty A.G., Levine M.N., Hirsch J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1989, 95:88S-97S.
217. Califf R.M., Fortin D.F., Tenaglia A.N., Sane D.C. Clinical risks of thrombolytic therapy. Am J Cardiol 1992, 69:12A-20A.
218. Muller D.W.M., Topol E.J. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med 1990, 113:949-960.
219. Cragg D.R., Friedman H.Z., Bonema J.D., et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991, 115:173-177.
220. ACC/AHA Task Force Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction ACC/AHA guidelines for the early management of patients with acute myocardial infarction. Circulation 1990, 82:664-707.
221. Tenaglia A.N., Califf R.M., Candela R.J., et al. Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. Am J Cardiol 1991, 68:1015-1019.
222. Gurwitz J.H., Goldberg R.J., Gore J.M. Coronary thrombolysis for the elderly?. JAMA 1991, 265:1720-1723.
223. Forman D.E., Bernal J.L.G., Wei J.Y. Management of acute myocardial infarction in the very elderly. Am J Med 1992, 93:315-326.
224. Pinto D.S., Kirtane A.J., Nallamothu B.K., et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: Implications when selecting a reperfusion strategy. Circulation 2006, 114:2019-2025.
225. Kanel W.B., Sorlie P., McNamara A.M. Prognosis after myocardial infarction. The Framingham Study. Am J Cardiol 1979, 44:53-59.
226. Tofler G.H., Stone P.H., Muller J.E., et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987, 9:473-482.
227. Silver M.J., Lincoff A.M., Topol E.J. Thrombolytic therapy for acute myocardial infarction in women: evidence for a "gender gap. Prim Cardiol 1995, 21:19-32.
228. Topol E.J., Califf R.M., Sigmon K.M., Lee K.L. Thrombolytic therapy for women with acute myocardial infarction: is there a gender gap? Cardiovasc Rev Rep 1995;16, 22-27.
229. Bates E.R., Topol E.J. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991, 18:1077-1084.
230. Lee L., Bates E.R., Pitt B., et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by shock. Circulation 1988, 78:1345-1351.
231. TRIUMPH Investigators Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007, 297:1657-1666.
232. Sane D.C., Califf R.M., Topol E.J., et al. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989, 111:1010-1022.
233. Irani M.S., White H.J., Sexon R.G. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 1995, 75:422-423.
234. Dotter C.T., Judkins M.P. Transluminal treatment of arteriosclerotic obstruction: description of a new technic and a preliminary report of its application. Circulation 1964, 30:654-670.
235. Gruentzig A.R., Kumpe D.A. Technique of percutaneous transluminal angioplasty with the Gruentzig balloon catheter. AJR Am J Roentgenol 1979, 132:547.
236. Gruentzig A.R., Senning A., Sigenthaler W.E. Non-operative dilatation of coronary artery stenosis-percutaneous transluminal coronary angioplasty. N Engl J Med 1979, 301:61.
237. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
238. Meyer J., Merx W., Schmitz H., et al. Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation 1982, 66:905-913.
239. Rentrop P., Blanke H., Karsch K.R., et al. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981, 63:307-317.
240. Rentrop P., Blanke H., Wiegand V., Karsch K.R. [Recanalization by catheter of the occluded artery after acute myocardial infarction (transluminal recanalization) (author's transl)]. Dtsch Med Wochenschr 1979, 104:1401-1405.
241. White H.D., Van de Werf F.J. Thrombolysis for acute myocardial infarction. Circulation 1998, 97:1632-1646.
242. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989, 320:618-627.
243. Rogers W.J., Baim D.S., Gore J.M., et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation 1990, 81:1457-1476.
244. O'Keefe J.J., Rutherford B., McConahay D., et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989, 64:1221-1230.
245. O'Neill W., Timmis G.C., Bourdillon P.D., et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986, 314:812-818.
246. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20.
247. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004, 44:E1-E211.
248. Gore J.M., Sloan M., Price T.R., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991, 83:448-459.
249. White H.D. Thrombolytic therapy in the elderly. Lancet 2000, 356:2028-2030.
250. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994, 343:311-322.
251. Zeymer U., Tebbe U., Essen R., et al. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. Am Heart J 1999, 137:34-38.
252. Zijlstra F., de Boer M.J., Hoorntje J.C., et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993, 328:680-684.
253. Grines C.L., Browne K.F., Marco J., et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993, 328:673-679.
254. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997, 336:1621-1628.
255. Wilson S.H., Bell M.R., Rihal C.S., et al. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001, 141:704-710.
256. Schomig A., Kastrati A., Dirschinger J., et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000, 343:385-391.
257. Aversano T., Aversano L.T., Passamani E., et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002, 287:1943-1951.
258. Grines C.L., Cox D.A., Stone G.W., et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999, 341:1949-1956.
259. Grines C.L., Westerhausen D.R., Grines L.L., et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002, 39:1713-1719.
260. Grzybowski M., Clements E.A., Parsons L., et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003, 290:1891-1898.
261. Tiefenbrunn A.J., Chandra N.C., French W.J., et al. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998, 31:1240-1245.
262. Danchin N., Vaur L., Genes N., et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. Circulation 1999, 99:2639-2644.
263. Ryan T.J., Ryan T.J., Jacobs A.K. Primary PTCA versus thrombolytic therapy: an evidence-based summary. Am Heart J 1999, 138:S96-S104.
264. Widimsky P., Budesinsky T., Vorac D., et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003, 24:94-104.
265. Andersen H.R., Nielsen T.T., Rasmussen K., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003, 349:733-742.
266. Le May M.R., Davies R.F., Dionne R., et al. Comparison of early mortality of paramedic-diagnosed ST-segment elevation myocardial infarction with immediate transport to a designated primary percutaneous coronary intervention center to that of similar patients transported to the nearest hospital. Am J Cardiol 2006, 98:1329-1333.
267. Nallamothu B.K., Bates E.R., Herrin J., et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005, 111:761-767.
268. Aversano T., Aversano L.T., Passamani E., et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002, 287:1943-1951.
269. Schwartz L., Bourassa M.G., Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988, 318:1714-1719.
270. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339:1665-1671.
271. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
272. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
273. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005, 294:1224-1232.
274. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006, 48:1339-1345.
275. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006, 48:931-938.
276. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998, 98:734-741.
277. Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000, 35:915-921.
278. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001, 344:1895-1903.
279. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957-966.
280. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003, 42:1879-1885.
281. Tcheng J.E., Kandzari D.E., Grines C.L., et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003, 108:1316-1323.
282. Gibson C.M., Kirtane A.J., Murphy S.A., et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006, 152:668-675.
283. Smith S.C., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001, 37:2215-2239.
284. Madan M., Radhakrishnan S., Reis M., et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol 2005, 95:1295-1301.
285. Buller C.E., Pate G.E., Armstrong P.W., et al. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol 2006, 22:511-515.
286. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003, 289:853-863.
287. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004, 292:696-703.
288. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358:1855-1863.
289. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
290. Dauerman H.L., Sobel B.E. Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol 2003, 42:646-651.
291. Spencer F.A., Goldberg R.J., Frederick P.D., et al. Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]). Am J Cardiol 2001, 88:107-111.
292. Scheller B., Hennen B., Hammer B., et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003, 42:634-641.
293. Le May M.R., Wells G.A., Labinaz M., et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005, 46:417-424.
294. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006, 367:569-578.
295. Sutton A.G., Campbell P.G., Graham R., et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004, 44:287-296.
296. Kunadian B., Sutton A.G., Vijayalakshmi K., et al. Early invasive versus conservative treatment in patients with failed fibrinolysis-no late survival benefit: the final analysis of the Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) randomized trial. Am Heart J 2007, 153:763-771.
297. Gershlick A.H., Stephens-Lloyd A., Hughes S., et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005, 353:2758-2768.
298. Wijeysundera H.C., Vijayaraghavan R., Nallamothu B.K., et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol 2007, 49:422-430.
299. de Lemos J.A., Antman E.M., Gibson C.M., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation 2000, 101:239-243.
300. Coulter S.A., Cannon C.P., Ault K.A., et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation 2000, 101:2690-2695.
301. Schneider D.J., Tracy P.B., Mann K.G., Sobel B.E. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997, 96:2877-2883.
302. We Should Intervene Following Thrombolysis? (SWIFT) Trial Study Group. SWIFT trial of delayed elective intervention vs conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ 1991, 302:555-560.
303. Madsen J.K., Grande P., Saunamaki K., et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997, 96:748-755.
304. Collet J.P., Montalescot G., Le M.M., et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol 2006, 48:1326-1335.
305. Hochman J.S., Lamas G.A., Buller C.E., et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006, 355:2395-2407.
306. Herrmann H.C., Moliterno D.J., Ohman E.M., et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot). Trial. J Am Coll Cardiol 2000, 36:1489-1496.
307. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001, 357:1905-1914.
308. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 2005, 150:116-122.
309. Krumholz H.M., Gross C.P., Peterson E.D., et al. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. Am Heart J 2003, 146:839-847.
310. Simoons M.L., Maggioni A.P., Knatterud G., et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993, 342:1523-1528.
311. Brass L.M., Lichtman J.H., Wang Y., et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000, 31:1802-1811.
312. White H.D., Barbash G.I., Califf R.M., et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996, 94:1826-1833.
313. Andersen H.R., Nielsen T.T., Rasmussen K., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003, 349:733-742.
314. de Boer M.J., Ottervanger J.P., van't Hof A.W., et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002, 39:1723-1728.
315. Goldenberg I., Matetzky S., Halkin A., et al. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2003, 145:862-867.
316. Grines C.L. Senior PAMI: a prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction 2005, Presented at Transcatheter Therapeutics, Washington, DC.
317. Mehta R.H., Sadiq I., Goldberg R.J., et al. Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2004, 147:253-259.
318. Dauerman H.L., Ryan T.J., Piper W.D., et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 2003, 15:380-384.
319. Babaev A., Frederick P.D., Pasta D.J., et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005, 294:448-454.
320. Hochman J.S., Buller C.E., Sleeper L.A., et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J Am Coll Cardiol 2000, 36(3 Suppl A):1063-1070.
321. Dzavik V., Sleeper L.A., Cocke T.P., et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003, 24:828-837.